Jyoji Nakagawara Selected Research

Jyoji Nakagawara Research Topics

Disease

32	Stroke (Strokes) 06/2022 - 11/2009
16	Ischemic Stroke 01/2019 - 07/2006
15	Atrial Fibrillation 06/2022 - 01/2011
13	Hemorrhage 06/2022 - 03/2014
12	Cerebral Hemorrhage 01/2018 - 09/2009
8	Intracranial Hemorrhages (Intracranial Hemorrhage) 09/2015 - 03/2010
7	Embolism (Embolus) 06/2022 - 04/2012
4	Body Weight (Weight, Body) 06/2022 - 11/2014
3	Myocardial Infarction 06/2022 - 12/2019
3	Thromboembolism 04/2020 - 01/2012
3	Moyamoya Disease (Moya-Moya Disease) 01/2019 - 06/2004
3	Hematoma 01/2018 - 12/2012
3	Cerebral Infarction 01/2018 - 11/2006
3	Middle Cerebral Artery Infarction (Middle Cerebral Artery Syndrome) 10/2013 - 03/2010
2	Hypertension (High Blood Pressure) 03/2020 - 01/2011
2	Infarction (Infarctions) 08/2016 - 01/2010
2	Traumatic Brain Injuries (Traumatic Brain Injury) 01/2013 - 10/2010
2	Brain Ischemia (Cerebral Ischemia) 01/2012 - 06/2004
2	Hyperglycemia 01/2012 - 11/2009
1	Diabetes Mellitus 01/2021
1	Vascular Diseases (Vascular Disease) 01/2021
1	Transient Ischemic Attack 01/2019
1	Inflammation (Inflammations) 12/2017
1	Dementia (Dementias) 12/2017
1	Brain Edema (Cerebral Edema) 09/2015
1	Nervous System Diseases (Neurological Disorders) 09/2014
1	Subarachnoid Hemorrhage (Aneurysmal Subarachnoid Hemorrhage) 02/2014
1	Intracranial Vasospasm 02/2014
1	Brain Concussion (Cerebral Concussion) 01/2013
1	Wounds and Injuries (Trauma) 01/2013
1	Brain Infarction 09/2011
1	Myocardial Ischemia (Ischemic Heart Diseases) 01/2011
1	Contusions 10/2010
1	Urinary Bladder Neoplasms (Bladder Cancer) 04/2010
1	Anemia 04/2010
1	Hematuria 04/2010
1	Heart Failure 11/2009
1	Ischemia 06/2004

Drug/Important Bio-Agent (IBA)

20	Tissue Plasminogen Activator (Alteplase)FDA Link 05/2014 - 07/2006
11	RivaroxabanIBA 06/2022 - 11/2014
9	AnticoagulantsIBA 04/2020 - 01/2012
7	CreatinineIBA 06/2022 - 01/2018
5	Warfarin (Coumadin)FDA LinkGeneric 01/2018 - 01/2012
5	Antihypertensive Agents (Antihypertensives)IBA 03/2014 - 09/2009
3	Hydroxymethylglutaryl-CoA Reductase Inhibitors (HMG-CoA Reductase Inhibitors)IBA 02/2015 - 04/2010
3	iomazenilIBA 01/2013 - 10/2010
2	Factor Xa InhibitorsIBA 07/2019 - 04/2012
2	Vitamin K FDA Link 01/2018 - 04/2012
2	Nicardipine (Dagan)FDA LinkGeneric 11/2014 - 12/2012
2	GABA-A Receptors (GABA(A) Receptor)IBA 01/2013 - 10/2010
1	Cytochrome P-450 CYP2C19IBA 01/2019
1	Proteins (Proteins, Gene)FDA Link 01/2019
1	Clopidogrel (Plavix)FDA Link 01/2019
1	Factor Xa (Coagulation Factor Xa)IBA 01/2018
1	Amyloid (Amyloid Fibrils)IBA 12/2017
1	Biomarkers (Surrogate Marker)IBA 12/2017
1	Hemoglobins (Hemoglobin)IBA 08/2016
1	Desmodus rotundus salivary plasminogen activator alpha 1IBA 09/2015
1	Blood Glucose (Blood Sugar)IBA 03/2015
1	Platelet Aggregation Inhibitors (Antiplatelet Drugs)IBA 11/2014
1	Oxygen (Dioxygen)IBA 09/2014
1	Eicosapentaenoic AcidIBA 02/2014
1	sphingosine phosphorylcholineIBA 02/2014
1	rho-Associated KinasesIBA 02/2014
1	MCOIBA 10/2013
1	Pharmaceutical PreparationsIBA 07/2013
1	Glucose (Dextrose)FDA LinkGeneric 04/2013
1	thiamine triphosphorate (TTP)IBA 01/2013
1	Dabigatran FDA Link 04/2012
1	4- Acetamido- 4'- isothiocyanatostilbene- 2,2'- disulfonic Acid (SITS)IBA 01/2012
1	LipidsIBA 01/2012
1	BenzodiazepinesIBA 01/2012
1	acceleratory factor from growth hormone (AcG)IBA 01/2012
1	candesartanIBA 09/2011
1	candesartan cilexetil (Amias)FDA Link 09/2011
1	Fibrinolytic Agents (Antithrombotic Agents)IBA 01/2011
1	Inosine Monophosphate (IMP)IBA 06/2004
1	Acetazolamide (Diamox)FDA LinkGeneric 06/2004

Therapy/Procedure

17	Therapeutics 01/2018 - 01/2011
2	Aftercare (After-Treatment) 03/2010 - 01/2010
1	Length of Stay 01/2018
1	Intravenous Administration 01/2013
1	Secondary Prevention 09/2011
1	Blood Transfusion (Blood Transfusions) 04/2010
1	Decompression 01/2010
1	Thrombolytic Therapy 11/2006